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Incidental Live-Saving
Polymerase Chain Reaction
in a Case of Prosthetic Valve
Dual-Pathogen Endocarditis
To the Editor—An otherwise healthy
44-year-old woman (a resident of a moun-
tainous region of Switzerland) presented
to the emergency department with acute
onset of fever, myalgia, and disorientation.
On physical examination, she was in shock
without an evident infectious source. Lab-
oratory analyses revealed leukocytosis
(WBC count, cells/L) and an927,000 10
elevated C-reactive protein level (260 mg/
L). The patient had a history of congenital
left ventricular inflow and outflow tract
obstruction that was surgically corrected
at the age of 15 years. In 1986 and 1996,
she had infectious endocarditis of the aor-
tic valve due to Staphylococcus aureus; the
aortic valve was replaced by a homograft
in 1990.
Transesophageal echocardiography
showed vegetations on the aortic valve
and possibly also on the mitral valve, with
severe aortic and moderate mitral regur-
gitation. Therapy with vancomycin, gen-
tamicin, and rifampicin was initiated.
Blood cultures grew methicillin-sensitive
S. aureus, supporting a diagnosis of S.
aureus prosthetic valve endocarditis, and
treatment was changed to flucloxacillin
and rifampicin. The clinical course was
complicated by acute renal failure, severe
thrombopenia, and multiple septic em-
boli (in the brain, skin, retina, and
spleen). After 4 weeks of antibiotic ther-
apy, the aortic and mitral valves were re-
placed by mechanical prostheses. Cul-
tures of the aortic valve were sterile, but
broad-range eubacterial PCR had results
positive for Coxiella burnetii. Serologic
results confirmed chronic Q-fever (phase
1 IgG titer, 1:6400; phase 1 IgA titer, 1:
200; phase 2 IgG titer, 1:12,800; and
phase 2 IgA titer, 1:400); analysis of
stored serum samples from the patient
revealed that the infection had been ac-
quired in the previous 12 months. Thus,
the final diagnosis was chronic Q-fever
prosthetic valve endocarditis complicated
by acute S. aureus prosthetic valve en-
docarditis. The postoperative course was
uncomplicated. S. aureus prosthetic valve
endocarditis was treated for a total of 6
weeks with flucloxacillin and rifampicin.
For Q-fever endocarditis, therapy with
doxycycline and hydroxychloroquine was
introduced and will be continued
until the phase 1 IgG titer is !1:400, with
a minimum treatment duration of 18
months. At the most recent follow-up
visit, 10 months after the initial presen-
tation, the patient was asymptomatic and
titers of anti-Coxiella antibodies were de-
creasing (phase 1 IgG titer, 1:3200; phase
1 IgA titer, 1:50; phase 2 IgG titer, 1:
6400; phase 2 IgA titer, 1:100).
This case is remarkable for the simul-
taneous implication of two different bac-
terial species in the pathogenesis of in-
fective endocarditis, with one of the
pathogens being discovered incidentally.
Reports in the literature on dual-pathogen
endocarditis are scarce; 2 cases with con-
comitant streptococcal and Q-fever en-
docarditis have been previously described
in a large, prospective French study [1].
Our patient had underlying cardiac ab-
normalities predisposing her to C. burnetii
endocarditis and resided in an area of
Switzerland with a seroprevalence of Cox-
iella species infection up to 30% [2]. Nev-
ertheless, C. burnetii infection was not sus-
pected, because all clinical manifestations
were compatible with staphylococcal pros-
thetic valve endocarditis. The diagnosis of
Q-fever endocarditis was thus a lucky
strike, which is disconcerting given the
poor prognosis of unrecognized chronic
Coxiella infection. In view of our experi-
ence, we believe that C. burnetii serologic
analysis or PCR testing of heart valve tis-
sue are worth performing in all patients
with infective endocarditis who have a
preexisting valvulopathy and live in a re-
gion in which Q-fever is endemic, regard-
less of whether another etiological agent
has been identified or not.
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In Patients with Type 2
Diabetes Mellitus, Are
Glycosylated Hemoglobin
Levels Higher for Those
with Helicobacter pylori
Infection Than Those
without Infection?
To the Editor—In recent years, a sig-
nificant association has been reported be-
tween cardiovascular diseases, diabetes,
and dyslipidemia and Helicobacter pylori
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Figure 1. Comparative glycosylated hemoglobin levels among patients with type 2 diabetes
mellitus, by status of Helicobacter pylori infection.
infection [1–6]. However, there are con-
flicting reports [2], and lack of data from
Latin American should prompt local stud-
ies for establishing the relationship be-
tween H. pylori and such chronic diseases.
We hypothesized that among Peruvian pa-
tients with type 2 diabetes mellitus, H. py-
lori infection may be associated with re-
duced metabolic control of disease. There-
fore, we evaluated the relationship be-
tween glycosylated hemoglobin (HbA1c)
levels and H. pylori infection in a cohort
of patients with type 2 diabetes mellitus
from Peru.
We enrolled 75 patients (40 men and
35 women; mean age  SD, 52.8 6.6
years) affected by type 2 diabetes mellitus
with a mean (SD) diabetic duration of
years, all of whom had similar8.2 4.3
geographical origin and socioeconomic
status. Body mass index; cholesterol, tri-
glyceride, and HbA1c levels; and diabetic
complications were evaluated. H. pylori in-
fection was demonstrated through use of
the urea breath test and biopsy of gastric
tissue.
Most evaluated patients had a certain
degree of gastritis (89.3% moderated su-
perficial chronic gastritis), and 65.3% were
infected with H. pylori. Although we did
not find a statistically significantly higher
incidence of H. pylori infection among pa-
tients with type 2 diabetes mellitus who
disease was poorly controlled (HbA1c,
17.0%) than among those with appropri-
ate disease control (HbA1c, !7.0%)—23
(71.9%) of 32 patients versus 26 (60.5%)
of 43 patients (OR, 1.67; CI 95%, 0.56–
5.03; ; )—the levels2x p 0.61 Pp .434Yates
of HbA1c were significantly increased
among infected patients, compared with
uninfected patients (mean  SD HbA1c,
versus ;7.63% 0.23% 7.25% 0.49%
Mann-Whitney U, 442.0; Wilcoxon W,
793.0; ; ) (figure 1).Zp2.171 Pp .03
We found no statistically significant dif-
ference for body mass index or cholesterol
or triglyceride levels between those with
or without H. pylori infection.
Previous studies have demonstrated
that there is a high prevalence of H. pylori
infection among diabetic patients and that
it is correlated with dyspeptic symptoms,
as we see in our study [1]. Such findings
support the hypothesis that permanent
eradication of H. pylori would improve
metabolic control of diabetes and may re-
duce the development of diabetes com-
plications [3–5]. More importantly, dia-
betic subjects who have complications of
cardiovascular autonomic neuropathy and
dyspepsia are at high risk of H. pylori in-
fection and should be carefully investi-
gated and considered for eradication ther-
apy [1]. Therefore, urea breath test as fol-
low-up screening seems to be a useful tool
to use to detect patient infection and re-
infection, which would optimize the abil-
ity to control glucose levels [3, 5].
These preliminary findings, which need
to be confirmed and extended in further
studies, give evidence that H. pylori infec-
tion influences metabolic control among
adults with type 2 diabetes mellitus; pre-
vious studies have demonstrated these
findings among children and adolescents
with type 1 diabetes mellitus [6]. Given
the high prevalence of H. pylori infection
that is found among these diabetic subjects
and its influence on control of glucose lev-
els, screening for such patients should be
performed to aid in reducing the rate of
infection and to improve the control of
glucose levels.
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Figure 1. Clinical rate of otitis media and the common cold diagnosed in young children, aged 0–4 years, during 4 sample years. Winter weeks
appear at the midpoints of the horizontal axes.
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Comment on the Cover
To the Editor—We are pleased to see an
illustration by Serefeddin Sabuncuoglu as
the cover art of the 15 May 2007 issue of
Clinical Infectious Diseases and deeply ap-
preciate the editorial decision to highlight
it as an important piece of work in the
history of the struggle against infectious
diseases. However, some corrections are
required to improve the text that aims to
explain the illustration.
First, there is a high degree of agreement
among the experts that the correct name
of the author of the manuscript from
which the image was taken, and presum-
ably the physician in the illustration, is
Serefeddin Sabuncuoglu, who lived and
practiced medicine in northern Anatolia
during the 15th century [1]. His birth and
death dates are almost accurately docu-
mented as 1385 and 1470, respectively,
which is another point that needs clarifi-
cation in the text describing the cover.
Secondly, Serefeddin Sabuncuoglu was
a member of a Turkish family with no
known Arabic connection. It seems that
the Arab surgeon Albucasis’s book at-Tas-
rif, which served as a main resource to
Serefeddin Sabuncuoglu’s book Cerrahi-
yetu¨’l Haniyye, and the Arabic script of the
text led to a false impression that the au-
thor was an Arab physician. In addition,
the text of Sabuncuoglu’s book, which is
housed in the Bibliotheque Nationale, is
written in Turkish. Several articles derived
from this handwritten manuscript can be
searched for in the Medline database.
Finally, because of the unique illustra-
tions, all of which are lacking in Albu-
casis’s book, and because of numerous
original additions embedded in the text,
Serefeddin Sabuncuoglu’s book is clearly
more than a translation. The idea that
medical procedures may be depicted for
teaching purposes regardless of religious
prohibitions is revolutionary in nature and
has survived and developed over centuries,
as is shown in the cover illustration.
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Viral Infections and Acute
Otitis Media in Young
Children
To the Editor—We read with interest
the article by Chonmaitree et al. [1], which
highlights the association between viral re-
spiratory tract infections and acute otitis
media (AOM) complication in young
